Dbv Technologies SA DBV:Euronext Paris

RT Quote | Exchange | EUR
Last | 03/28/24 CET
1.33UNCH (UNCH)
Volume
32,979
52 week range
1.10 - 4.30
Loading...
  • Open1.34
  • Day High1.35
  • Day Low1.31
  • Prev Close1.33
  • 52 Week High4.30
  • 52 Week High Date05/15/23
  • 52 Week Low1.10
  • 52 Week Low Date02/19/24

Key Stats

  • Market Cap138.07M
  • Shares Out96.21M
  • 10 Day Average Volume46,441.8
  • Dividend-
  • Dividend Yield-
  • Beta-1.24
  • YTD % Change-28.02

KEY STATS

  • Open1.34
  • Day High1.35
  • Day Low1.31
  • Prev Close1.33
  • 52 Week High4.30
  • 52 Week High Date05/15/23
  • 52 Week Low1.10
  • 52 Week Low Date02/19/24
  • Market Cap138.07M
  • Shares Out96.21M
  • 10 Day Average Volume46,441.8
  • Dividend-
  • Dividend Yield-
  • Beta-1.24
  • YTD % Change-28.02

RATIOS/PROFITABILITY

  • EPS (TTM)-0.99
  • P/E (TTM)-1.35
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Dbv Technologies SA

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from...
Michel De Rosen
Non-Executive Independent Chairman of the Board
Daniel Tasse
Chief Executive Officer, Director
Virginie Boucinha
Chief Financial Officer
Address
177-181 avenue Pierre Brossolette
Montrouge
92120
France